⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972652 | 0.75 | — | — | |
| SCHEMBL974240 | 0.75 | — | — | |
| SCHEMBL534250 | 0.73 | — | — | |
| SCHEMBL972014 | 0.71 | PKM (0.30) | — | |
| SCHEMBL1339121 | 0.70 | — | — | |
| SCHEMBL577365 | 0.70 | — | — | |
| SCHEMBL933217 | 0.70 | — | — | |
| SCHEMBL14958000 | 0.69 | KDM4E (0.30) | — | |
| SCHEMBL2089485 | 0.69 | MAOB (0.41) | — | |
| SCHEMBL2095409 | 0.69 | SMN1; SMN2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2022-07-07 | — | — | US | disclosed |
| US-20220117946-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | EyePoint Pharmaceuticals, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2020-10-29 | — | — | US | disclosed |
| EP-3323815-B1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20200253936-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2020-08-13 | — | — | US | disclosed |
| CN-1922159-A | Benzamide derivatives and their use as glucokinase activating agents | ASTRAZENECA AB (SE) | 2007-02-28 | — | — | CN | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1718624-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | disclosed |
| CN-1777589-A | Heteroarylcarbamoylbenzene derivatives | BANYU PHARMA CO LTD (JP) | 2006-05-24 | — | — | CN | disclosed |
| CN-1747951-A | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMA CO LTD (JP) | 2006-03-15 | — | — | CN | disclosed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |